COST MINIMIZATION ANALYSIS (CMA) TERAPI INHALASI BUDESONIDE-FORMOTEROL VS FLUTIKASON-SALMETEROL PADA PASIEN ASMA DI RSUD SULTAN SURIANSYAH
DOI:
https://doi.org/10.36387/jifi.v6i3.1663Kata Kunci:
Asma, CMA, Farmakoekonomi, Seretide, SymbicortAbstrak
ICS-LABA combination inhalation therapy is the main recommendation in asthma management based on the latest guidelines in 2019 published by the Global Intiative for Asthma (GINA). Symbicort (budesonide-formoterol) and Seretide (fluticasone-salmeterol) are ICS-LABA combinations in one inhaler that are widely used in Indonesia. The purpose of this study is to determine the most cost-minimize therapy based on cost minimization analysis (CMA) method among two inhaled therapies that were proven to have clinical equivalence. Secondary data collection was carried out retrospectively on medical record data & records of treatment costs for asthma patients, in the January-December 2022 time period at the Outpatient Installation of Sultan Suriansyah Hospital, Banjarmasin City, and 70 samples were obtained in accordance with the research criteria. Data analysis was carried out based on pharmacoeconomic approaches and comparative statistical tests with the Mann-Whitney U method. The results showed that direct medical costs of Seretide group (IDR 220,403) were lower than those of Symbicort group (IDR 237,677). The results of comparative statistical test Mann-whitney showed that there was a significant difference in direct medical costs between the two inhaled therapies (p value 0.021 < 0.05). It was concluded that ICS-LABA inhalation therapy using Seretide was the most cost-minimizing therapy.
Referensi
Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract [Internet]. 2017;3(1):1–11. Available from: http://dx.doi.org/10.1186/s40733-016-0029-3
Kementerian Kesehatan Republik Indonesia. Laporan_Nasional_RKD2018_FINAL.pdf [Internet]. Badan Penelitian dan Pengembangan Kesehatan. 2018. p. 674. Available from: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf
Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: Reshaping the concept of asthma management. Allergy, Asthma Clin Immunol [Internet]. 2020;16(1):1–11. Available from: https://doi.org/10.1186/s13223-020-00472-8
Jennifer Y, Albert M, Kartik S. Asthma: Diagnosis and Treatment. Eur Med J. 2018;3(4):111–21.
Khoriyah S, Lestari K. Review Artikel: Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia. Farmaka. 2018;16(3):134–45.
Aalbers R, Backer V, Kava TTK, Omenaas ER, Sandström T, Jorup C, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20(2):225–40.
Andriyana K, Ismunandar A, Maulana L. Analisis Efektivitas Biaya Penggunaan Dry Powder Inhaler pada Pasien Asma di Klinik Paru RSUM Siti Aminah Bumiayu 2021. Pharm Perad J. 2022;2(2):66–74.
Fuseini H, Newcomb DC. Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep. 2017;17(3):19.
Pakkasela J, Ilmarinen P, Honkamäki J, Tuomisto LE, Andersén H, Piirilä P, et al. Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. 2020;20(1):1–9.
Lindmark B. Review: Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma. Ther Adv Respir Dis. 2008;2(5):279–99.
Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency. Eur Respir J. 1997;10(11):2484–9.
Price DB, Colice G, Israel E, Roche N, Postma DS, Guilbert TW, et al. Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Res [Internet]. 2016;2(2):1–10. Available from: http://dx.doi.org/10.1183/23120541.00106-2015
Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29(3):587–95.
Kuna P. Treatment comparison of budesonideformoterol with salmeterolfluticasone propionate in adults aged ≥16 years with asthma: Post hoc analysis of a randomized, double-blind study. Clin Drug Investig. 2010;30(9):565–79.
Unduhan
Diterbitkan
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2024 Jurnal Insan Farmasi Indonesia
Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
